Five Prime Therapeutics (FPRX) Misses Q3 EPS by 21c

November 4, 2016 8:12 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.72), $0.21 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $7.5 million.

Five Prime continues to expect full-year 2016 net cash used in operating activities to be less than $120 million, comprising less than $90 million used in operations and less than $30 million used for tax payments. The company estimates ending 2016 with more than $400 million in cash, cash equivalents and marketable securities.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment